Avidity Biosciences CSO Art Levin and CEO Sarah Boyce

FDA slaps a par­tial hold on Avid­i­ty's mAb-siR­NA ther­a­py, paus­ing en­roll­ment in mus­cle weak­ness dis­ease study

Avid­i­ty Bio­sciences will have to wait to en­roll new pa­tients in a Phase I/II study of its ther­a­py for my­oton­ic dy­s­tro­phy type 1, or DM1 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.